Medtech Tip Of The Week - Technology Meets Physician and Patient

Medtech Tip Of The Week - Technology Meets Physician and Patient

From my work of 30 years in bringing dozens of medtech products to market successfully I have always seen the best way to success is to validate the technology clinically in each geographic area that we wanted to pursue with the local Key Opinion Leaders (KOL); define well the value proposition and conduct the clinical studies needed to get the informal local stamp of approval. It doesn't hurt along the way to have the KOL publish the data you gather in an international conference or journal as well, but to clarify the validation work done does not have to be at the quality of a published article - it can be a very simple trial.

Otherwise you will always get the resistance and statements like "in our country medicine is practiced differently" or "our patients are different", etc.

Today, In helping young companies go to market I see the tendency to try to skip the clinical validation stage at least on the local level - skip it and your product will not succeeed in the market or at least not as well as it could have with proper clinical work.

Once you have the data, with today's technologies you can spread the word quickly, utilize the result to your benefit and educate the world on how your product is being used in all parts of the world.

Now, Let's go sell something!

Rani Shifron 施逢霖

Digital Health & Medtech Innovation Scaler | Driving Breakthroughs in Healthcare Technology | Transforming Patient Care with Data-Driven Solutions | Passionate about Improving Lives | Global Thinker ??

8 年

Have seen a lot of physicians resist change or resist new groundbreaking technologies only to adopt them once sufficient clinical results and sufficient training has been provided

回复
Michael Fruhling, MBA

Technology Scouting and Business Development Services To Help Innovators Make The Right Connections. Ohio State University Innovation Lecturer.

8 年

Good advice. External technology providers seeking to attract large corporate customers' interest in their tech should also mind this advice or risk failing to earn support. I've seen corporate "gunslingers" shoot down external technology candidates by raising sufficient skepticism to stall efforts to develop advocates.

Dr. Ali Tinazli

Chief Executive Officer @ lifespin GmbH | Pioneering Deep Health

8 年

Exactly - skipping the clinical data means having no real product. We need more of a culture such as "Technology meets Patient", "Technology meets NP", "Technology meets MD".

要查看或添加评论,请登录

Rani Shifron 施逢霖的更多文章

社区洞察

其他会员也浏览了